Halozyme Therapeutics Inc. (HALO)

Business: Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.

IPO Date: 16-Mar-2004

Pres, CEO & Director: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Sr. VP & Chief Technical Officer: Dr. Michael J. LaBarre

Listing: NASDAQ: HALO

Country: United States

Headquarters: San Diego, CA

Website: https://www.halozyme.com

Market cap: $6,136.02 Mln

Revenue (TTM): $471.57 Mln

Earnings (TTM): $434.92 Mln

Cash: $786.14 Mln

Total Debt: $877.65 Mln

Insider's Holding: 1.05%

Liquidity: Low

52 Week range: $31.36 - 48.54

Shares outstanding: 137,950,000

10 Years Aggregate:

• CFO: $105.37 Mln
• EBITDA: $83.56 Mln
• Net Profit: $101.54 Mln